Loading
In eleven people with advanced melanoma given cyclophosphamide and then their own melanoma-targeting T cells, one had a complete remission lasting over three years, and the cells that survived changed into long-lived memory cells.
Eleven patients with refractory, progressive metastatic melanoma received cyclophosphamide alone as conditioning before infusion of blood-derived, antigen-specific CD8+ CTL clones, followed by low-dose or high-dose IL-2 (PNAS 2012). The infused clones had an effector memory phenotype, and those that persisted long term acquired central memory qualities in vivo (PNAS 2012).
Infused T-cell clones can convert to a central memory type in the body, which may underlie lasting benefit.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Proceedings of the National Academy of Sciences, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/